{
    "clinical_study": {
        "@rank": "18483", 
        "arm_group": {
            "arm_group_label": "BMS-791325 (oral) and [13C]-BMS-791325 (IV)", 
            "arm_group_type": "Experimental", 
            "description": "BMS-791325 single dose tablet orally and [13C]-BMS-791325 single dose solution intravenously on specific days"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the absolute bioavailability of 150 mg oral dose\n      of BMS-791325 relative to 100 \u00b5g IV infusion of [13C]-BMS-791325."
        }, 
        "brief_title": "Absolute Bioavailability of BMS-791325", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C Virus Infection", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Virus Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Purpose: Other: Protocol is designed to assess the absolute bioavailability of 150\n      mg (2x75 mg tablets) BMS-791325 administered orally"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          1. Healthy subjects as determined by no clinically significant deviation from normal in\n             medical history, physical examination, ECGs, and clinical laboratory determinations\n\n          2. Men and women ages 18 to 49 years, inclusive\n\n          3. Women of childbearing potential (WOCBP) must not be pregnant or breastfeeding\n\n               -  WOCBP and men who are sexually active with WOCBP must agree to follow protocol\n                  mandated instructions for method(s) of contraception during and after the study\n\n        Exclusion Criteria:\n\n          1. Any significant acute or chronic medical illness\n\n          2. Any current or recent gastrointestinal disease or surgery that could impact upon the\n             absorption of study drug\n\n          3. Inability to tolerate oral medication\n\n          4. Inability to be venipunctured and/or tolerate venous access\n\n          5. Use of tobacco-containing or nicotine-containing products within 6 months\n\n          6. Recent (within 6 months of study drug administration) drug or alcohol abuse as\n             defined in Diagnostic and Statistical Manual of Mental Disorders (4th Edition)(DSM\n             IV), Diagnostic Criteria for Drug and Alcohol Abuse\n\n          7. Any of the following on 12-lead electrocardiogram (ECG) prior to study drug\n             administration at screening or Day -1, confirmed by repeat\n\n        i)PR \u2265 210 msec\n\n        ii)QRS \u2265 120 msec\n\n        iii)QT \u2265 500 msec\n\n        iv)QTcF \u2265 450 msec\n\n        v)Second or third degree heart block\n\n        h) Positive urine screen for drugs of abuse\n\n        i) Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, r HIV-1,\n        -2 antibodies\n\n        j) Any of the following screening or Day -1 laboratory results outside the ranges\n        specified below as defined by the laboratory, confirmed by repeat analysis:\n\n        i)Serum creatinine > upper limit of normal (ULN)\n\n        ii)Alanine aminotransferase (ALT) > ULN\n\n        iii)Aspartate aminotransferase(AST) > ULN\n\n        iv)Total bilirubin > ULN\n\n        k) History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112110", 
            "org_study_id": "AI443-109", 
            "secondary_id": "2013-004645-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "BMS-791325 (oral) and [13C]-BMS-791325 (IV)", 
                "intervention_name": "BMS-791325", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BMS-791325 (oral) and [13C]-BMS-791325 (IV)", 
                "intervention_name": "[13C]-BMS-791325", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "contact": {
                "last_name": "Site 0001"
            }, 
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom", 
                    "state": "Nottinghamshire", 
                    "zip": "NG11 6JS"
                }, 
                "name": "Local Institution"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of the Absolute Oral Bioavailability of BMS-791325 in Healthy Subjects", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Absolute bioavailability of 150 mg (2x75 mg tablets) BMS-791325 administered orally will be established by calculating the ratio of the dose normalized AUC(INF) of oral dose with that of 100 \u00b5g IV infused dose.", 
            "measure": "Absolute oral bioavailability (F) of BMS-791325", 
            "safety_issue": "No", 
            "time_frame": "48 hours from time of oral dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112110"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Serious adverse events (SAEs)\nAdverse events (AEs)\nPhysical examinations (PEs)", 
                "measure": "Safety and tolerability of BMS-791325 by the occurrence of AEs and SAEs, abnormalities in vital sign measurements exceeding pre-defined thresholds, findings on ECGs and PEs, and abnormalities and marked abnormalities in clinical laboratory test.", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 predose and 2 hours post-dose, Day 2 and Day 3"
            }, 
            {
                "measure": "Maximum observed plasma concentration (Cmax) of BMS-791325 (oral dose) and [13C]-BMS-791325 (IV dose)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose"
            }, 
            {
                "measure": "Time of maximum observed plasma concentration (Tmax) of BMS-791325 (oral dose) and [13C]-BMS-791325 (IV dose)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of BMS-791325 (oral dose) and [13C]-BMS-791325 (IV dose)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-791325 (oral dose) and [13C]-BMS-791325 (IV dose)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose"
            }, 
            {
                "measure": "Terminal plasma half-life (T-HALF) of BMS-791325 (oral dose) and [13C]-BMS-791325 (IV dose)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose"
            }, 
            {
                "measure": "Total clearance (CLT) of [13C]-BMS-791325 (IV dose)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose"
            }, 
            {
                "measure": "Volume of distribution at steady-state (Vss) of [13C]-BMS-791325 (IV dose)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}